CN118574855B - 特异性结合psma和cd3的抗原结合分子及其医药用途 - Google Patents

特异性结合psma和cd3的抗原结合分子及其医药用途

Info

Publication number
CN118574855B
CN118574855B CN202380017887.2A CN202380017887A CN118574855B CN 118574855 B CN118574855 B CN 118574855B CN 202380017887 A CN202380017887 A CN 202380017887A CN 118574855 B CN118574855 B CN 118574855B
Authority
CN
China
Prior art keywords
psma
seq
amino acid
acid sequence
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202380017887.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN118574855A (zh
Inventor
应华
石金平
杨昊
张小敏
金薪盛
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN202610611775.5A priority Critical patent/CN122483210A/zh
Publication of CN118574855A publication Critical patent/CN118574855A/zh
Application granted granted Critical
Publication of CN118574855B publication Critical patent/CN118574855B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380017887.2A 2022-02-07 2023-02-07 特异性结合psma和cd3的抗原结合分子及其医药用途 Active CN118574855B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202610611775.5A CN122483210A (zh) 2022-02-07 2023-02-07 特异性结合psma和cd3的抗原结合分子及其医药用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022101166846 2022-02-07
CN202210116684 2022-02-07
PCT/CN2023/074735 WO2023147784A1 (zh) 2022-02-07 2023-02-07 特异性结合psma和cd3的抗原结合分子及其医药用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610611775.5A Division CN122483210A (zh) 2022-02-07 2023-02-07 特异性结合psma和cd3的抗原结合分子及其医药用途

Publications (2)

Publication Number Publication Date
CN118574855A CN118574855A (zh) 2024-08-30
CN118574855B true CN118574855B (zh) 2026-05-12

Family

ID=87553110

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202380017887.2A Active CN118574855B (zh) 2022-02-07 2023-02-07 特异性结合psma和cd3的抗原结合分子及其医药用途
CN202610611775.5A Pending CN122483210A (zh) 2022-02-07 2023-02-07 特异性结合psma和cd3的抗原结合分子及其医药用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202610611775.5A Pending CN122483210A (zh) 2022-02-07 2023-02-07 特异性结合psma和cd3的抗原结合分子及其医药用途

Country Status (7)

Country Link
US (1) US20250043022A1 (cg-RX-API-DMAC7.html)
EP (1) EP4477669A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505611A (cg-RX-API-DMAC7.html)
KR (1) KR20240139065A (cg-RX-API-DMAC7.html)
CN (2) CN118574855B (cg-RX-API-DMAC7.html)
TW (1) TW202337902A (cg-RX-API-DMAC7.html)
WO (1) WO2023147784A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025031285A1 (zh) * 2023-08-04 2025-02-13 江苏恒瑞医药股份有限公司 抗psma抗体-药物偶联物及其医药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847594A (zh) * 2015-05-06 2018-03-27 詹森生物科技公司 前列腺特异性膜抗原(psma)双特异性结合剂及其用途
CN109476747A (zh) * 2016-05-27 2019-03-15 艾伯维生物制药股份有限公司 结合免疫调节性蛋白和肿瘤抗原的双特异性结合蛋白

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
AR107582A1 (es) 2016-02-03 2018-05-16 Amgen Res Munich Gmbh Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
US11773182B2 (en) * 2017-01-05 2023-10-03 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
JP7599205B2 (ja) * 2018-06-01 2024-12-13 アンヘレス セラピューティクス インコーポレイテッド 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
EP3936526A4 (en) 2019-03-06 2023-03-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. BIFUNCTIONAL FUSION PROTEIN AND PHARMACEUTICAL USE THEREOF
EP3986933A1 (en) * 2019-06-21 2022-04-27 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
EP4089111A4 (en) 2020-01-09 2023-10-04 Jiangsu Hengrui Medicine Co., Ltd. NEW POLYPEPTIDE COMPLEX

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847594A (zh) * 2015-05-06 2018-03-27 詹森生物科技公司 前列腺特异性膜抗原(psma)双特异性结合剂及其用途
CN109476747A (zh) * 2016-05-27 2019-03-15 艾伯维生物制药股份有限公司 结合免疫调节性蛋白和肿瘤抗原的双特异性结合蛋白

Also Published As

Publication number Publication date
US20250043022A1 (en) 2025-02-06
JP2025505611A (ja) 2025-02-28
KR20240139065A (ko) 2024-09-20
CN118574855A (zh) 2024-08-30
CN122483210A (zh) 2026-07-31
TW202337902A (zh) 2023-10-01
WO2023147784A1 (zh) 2023-08-10
EP4477669A1 (en) 2024-12-18
EP4477669A4 (en) 2026-02-25

Similar Documents

Publication Publication Date Title
US20250376519A1 (en) Antigen-binding molecule specifically binding to dll3 and cd3, and pharmaceutical use thereof
WO2023208182A1 (zh) 抗ccr8抗体及其用途
CN117480180A (zh) 特异性结合hgfr和egfr的抗原结合分子及其医药用途
EP4495139A1 (en) Antigen-binding molecule specifically binding to gprc5d and cd3 and medical use thereof
WO2023198015A1 (zh) 特异性结合psma和cd28的抗原结合分子及其医药用途
CN117813323A (zh) 抗klb抗体及用途
WO2022156739A1 (zh) 特异性结合bcma和cd3的抗原结合分子及其医药用途
US20250043022A1 (en) Antigen-binding molecule specifically binding to psma and cd3, and pharmaceutical use thereof
WO2024027815A1 (zh) 特异性结合gucy2c和cd3的抗原结合分子及其医药用途
CN117642427A (zh) 特异性结合cd38、bcma和cd3的抗原结合分子及其医药用途
CA3243665A1 (en) Antigen-binding molecule specifically binding to psma and cd3, and pharmaceutical use thereof
CN119013295A (zh) 特异性结合egfr和cd28的抗原结合分子及其医药用途
CN117916259A (zh) 特异性结合cgrp和pacap的抗原结合分子及其医药用途
TW202342549A (zh) 特異性結合flt3和cd3的抗原結合分子及其醫藥用途
HK40076302B (en) New polypeptide complex

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant